他拉唑帕尼治疗局部晚期HER-2阴性乳腺癌患者的临床疗效及安全性  

The clinical efficacy and safety of talazoparib in the treatment of locally advanced HER-2-negative breast cancer patients

作　　者：常成[1] 李晓川[1] 田晓卫[1] CHANG Cheng;LI Xiaochuan;TIAN Xiaowei(General Surgery Department,Qingdao Municipal Hospital,Shandong Qingdao 266001,China)

机构地区：[1]青岛市市立医院普外科,山东青岛266001

出　　处：《现代肿瘤医学》2022年第19期3519-3522,共4页Journal of Modern Oncology

摘　　要：目的:观察他拉唑帕尼治疗局部晚期人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)阴性乳腺癌患者的临床疗效及安全性。方法:选取我院2019年01月至2020年03月收治的80例局部晚期HER-2阴性乳腺癌患者为研究对象,采用随机数字表法分为对照组与观察组,每组各40例,对照组采用紫杉类联合蒽环类治疗,观察组加用他拉唑帕尼,4个周期后对比两组患者临床疗效及不良反应。结果:观察组患者客观缓解率为85.00%,与对照组(70.00%)相比较,差异有统计学意义(P<0.05);治疗前两组患者肿瘤标志物(CA15-3、CA125、癌胚抗原、循环肿瘤DNA)、血管内皮生长因子水平相比较,差异无统计学意义(P>0.05);治疗后与治疗前相比较,差异有统计学意义(P<0.05);观察组患者治疗后肿瘤标志物、血管内皮生长因子水平与对照组相比较,差异有统计学意义(P<0.05);观察组患者恶心/呕吐发生率为20.00%、骨髓抑制发生率为15.00%、白细胞计数/血小板计数减少发生率为10.00%,与对照组15.00%、15.00%、7.50%相比较,差异无统计学意义(P>0.05)。结论:他拉唑帕尼的应用有助于进一步提高局部晚期HER-2阴性乳腺癌患者客观缓解率且安全性高,值得推广使用。Objective:To observe the clinical efficacy and safety of talazoparib in the treatment of locally advanced human epidermal growth factor receptor-2(HER-2)negative breast cancer patients.Methods:We selected 80 locally advanced HER-2-negative breast cancer patients admitted to our hospital from January 2019 to March 2020 as the research objects,and divided them into a control group and an observation group by a random number table method,each with 40 cases.The control group treated with taxanes combined with anthracyclines,the observation group was treated with talazoparib,and the clinical efficacy and adverse reaction of the two groups were compared after 4 cycles.Results:The objective remission rate of the observation group was 85.00%,compared with 70.00%of the control group,the difference was statistically significant(P<0.05).The tumor markers of the two groups before treatment(CA15-3,CA125,carcinoembryonic antigen,circulating tumor DNA),vascular endothelial growth factor,the difference was not statistically significant(P>0.05),after treatment and before treatment,the difference was statistically significant(P<0.05).Observation group tumor markers,vascular endothelial growth after treatment compared with the control group,the difference was statistically significant(P<0.05).The observation group had 20.00%nausea/vomiting,15.00%bone marrow suppression,and 10.00%white blood cell count/platelet count reduction.Compared with control group of the 15.00%,15.00%,and 7.50%,the difference was not statistically significant(P>0.05).Conclusion:Talazoparib can improve the objective response rate and safety of locally advanced HER-2-negative breast cancer patients,which is worthy of promotion.

关 键 词：人表皮生长因子受体-2 乳腺癌 他拉唑帕尼 循环肿瘤DNA 

分 类 号：R737.9[医药卫生—肿瘤]